

Zydus starts Ph IV trial for Desidustat in patients with CKD induced anaemia

30 August 2022 | News

The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India



Ahmedabad-based Zydus Lifesciences has announced the commencement of Phase IV clinical trial for Desidustat in patients with Chronic Kidney Disease (CKD) induced anaemia.

CKD is predicted to become one of the most common causes of premature death by 2040 globally. It is estimated that 115.1 million people in India.

The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis-dependent and 502 dialysis-independent CKD patients with anaemia.

This multicentre post-marketing surveillance study will evaluate the safety of Desidustat for the treatment of anaemia in subjects with chronic kidney disease for 52 weeks.

Desidustat has been previously studied in randomised controlled clinical trials in over 1200 CKD patients, and is currently approved in India as Oxemia™ for the treatment of anemia in Chronic Kidney Disease (CKD) patients.